About Affinivax
Affinivax is a company based in Cambridge (United States) founded in 2013 was acquired by GSK in May 2022. Affinivax has raised $359.49 million across 5 funding rounds from investors including BlackRock, Bain Capital and T. Rowe Price. The company has 132 employees as of December 31, 2022. Affinivax operates in a competitive market with competitors including Brii Biosciences, Insmed, Neon Therapeutics, Eligo Bioscience and Lodo Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 132 as on 31 Dec, 2022
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Affinivax Inc
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Affinivax
Unlock access to complete
Funding Insights of Affinivax
Affinivax has successfully raised a total of $359.49M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $226 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Affinivax
Affinivax has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include BlackRock, Bain Capital and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage and late-stage biotech and finance companies are funded.
|
Locked | Locked | Locked | |
|
Multi-stage investment firm invests in healthcare and life sciences companies
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked |
Investor details for Affinivax
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Affinivax
Investment portfolio details for Affinivax
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Affinivax
Detailed financials for Affinivax
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Affinivax Comparisons
Peer comparison for Affinivax
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Affinivax
Affinivax operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Brii Biosciences, Insmed, Neon Therapeutics, Eligo Bioscience and Lodo Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of biologics to treat hepatitis B infection
|
|
| Locked | Locked | Locked |
Developer of small molecule inhibitors for rare lung diseases
|
|
| Locked | Locked | Locked |
Tumor-specific neoantigens are identified for personalized cancer vaccine development.
|
|
| Locked | Locked | Locked |
In vivo gene editing technology is developed for microbiome modulation.
|
|
| Locked | Locked | Locked |
Developer novel therapeutics to treat resistant infectious diseases and cancers using AI
|
Detailed competitors of Affinivax
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Affinivax
Complete news archive for Affinivax
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Affinivax
Affinivax was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Affinivax is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Affinivax is a funded company, having raised a total of $359.49M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Affinivax is 132.
Affinivax was established in 2013 in Cambridge, United States, within the biotechnology sector. Conjugate vaccines targeting infectious diseases are developed using the Multiple Antigen-Presenting System (MAPS) platform. Protective polysaccharides and proteins are conjugated into a single formulation through this technology. A broad immune response is elicited against pathogenic microorganisms. Operations center on advancing vaccine programs for various infectious threats.
Affinivax's top competitors include Brii Biosciences, Insmed and Osivax.
Affinivax has 16 investors. Key investors include BlackRock, Bain Capital, T. Rowe Price, Citadel, and Gates Foundation.